– IRELAND, Dublin – Ovoca Bio (LON: OVB), a biopharmaceutical company with a focus on women’s health, today announced the appointment of Anastasia Levashova to its Board as an Independent Non-Executive Director with immediate effect.
“We are delighted to welcome Anastasia to the board. She has deep asset management and investment banking experience and has long-standing relationships with financial institutions, private investors and other capital market participants. I look forward to working with Anastasia as we continue our development activities for our lead asset, orenetide, in major global markets.” said Chief Executive and Interim Chairman, Kirill Golovanov.
The company also announced the retirement of Leonid Skoptsov from the Board with immediate effect.
About Anastasia Levashova
Anastasia Levashova is a Portfolio Manager at Blackfriars Asset Management, a London, UK-based fund management boutique specializing in equities investment within global emerging and frontier markets. She has over 20 years of experience in investing across emerging markets working in New York, London, and Moscow in Bank of America Merrill Lynch, BNP Paribas, and Citibank.
Ms. Levashova holds a Ph.D. from Moscow Lomonosov State University in International Relations and an MA in International Finance from Columbia University.
For more information : https://ovocabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
